茵冠生物

Yinguan Biotech is a leading Chinese biotechnology company focused on the development of innovative cell therapies and regenerative medicine. Established in 2009 and headquartered in Shenzhen, the company has built a robust platform for the research, clinical transformation, and industrialization of mesenchymal stem cells (MSCs) and immune cells. Their clinical pipeline features advanced programs for liver cirrhosis and knee osteoarthritis, both of which have received IND approvals from the NMPA. Yinguan Biotech operates state-of-the-art GMP manufacturing facilities and maintains a network of regional cell banks to support its therapeutic offerings. The company collaborates extensively with top-tier hospitals and research institutions to advance the application of cell-based treatments for chronic and refractory diseases.